MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced Melanoma
A phase 1/2 trial of Nivolumab in melanoma, run by Perspective Therapeutics, now recruiting.
Overview
MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced Melanoma is a phase 1/2 interventional study registered as NCT05655312 by Perspective Therapeutics, with 300 participants planned, started 2023-06-01 and due to reach its primary completion in 2027-12-31. Interventions recorded: [203Pb]VMT01, [212Pb]VMT01, Nivolumab. Conditions listed: Recurrent Melanoma (Skin), Metastatic Melanoma, Melanoma Stage IV, Melanoma Stage III. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialLead-212 PSV359 Therapy for Patients With Solid Tumors
Shares Perspective Therapeutics, Lead-212.
- TrialTargeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors
Shares Perspective Therapeutics, Lead-212.
- AgentLead-212 VMT-alpha-NET
Shares Perspective Therapeutics, Lead-212.
- AgentLead-212 PSV359
Shares Perspective Therapeutics, Lead-212.
- IdeaFund alpha emitters beyond actinium-225: lead-212, terbium-149 and astatine-211
Shares Perspective Therapeutics, Lead-212.